Contamination due to alternative weight loss intervention (Intervention and control) Since semaglutide was first licenced for the treatment of obesity in 2021, tirzepatide, a GLP-1/GIP receptor agonist with has even greater efficacy of weight loss, has achieved FDA approval in 2023
Your clinician is the right person to discuss what's realistic for your specific situation
Ferreira ST, Lourenco MV, Oliveira MM, De Felice FG
+ Complete your health history
Orders placed after the cutoff or on weekends ship the next business day
Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis